Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma

NCT02860286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma
BAP1 Loss of Function

Interventions

DRUG: Tazemetostat

Sponsor

Epizyme, Inc.